Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epyg…
| Métrica | CVX.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -433.5% | -39.2% | -394.3% |
| ROA | -52.0% | -30.9% | -21.0% |
| Current Ratio | 0.30 | 2.73 | -2.43 |
| Debt / Equity | 2.06 | 0.28 | +1.78 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -52.0% | — |
| ✗Flujo de caja operativo positivo | −€12M | −€11M |
| ✗Rentabilidad sobre activos al alza | -52.0% | -24.2% |
| ✓Caja operativa/activos supera al ROA | -24.0% | ROA -52.0% |
| ✗Menos deuda a largo plazo | 24.7% | 23.1% |
| ✗Mejor liquidez (ratio corriente) | 0.30 | 1.28 |
| ✗Sin aumentar el nº de acciones | 40M | — |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.00 | 0.07 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -96.5% |
| ✓Deuda neta/EBITDA < 3x | -1.4x |
CARVOLIX cotiza a 5.26 EUR y tiene una capitalización bursátil de €327M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud